On that Sunday in late February 1949, five of America's top rheumatology specialists arrived in Rochester, Minnesota.
On the program: five days of small-group conferences with Dr Philip Showalter Hench.
Five months ago, Hench and her colleagues at the Mayo Clinic witnessed a miracle: Mrs. G., bedridden by severe rheumatoid arthritis resistant to treatment, was the first to be treated with a brand new molecule.
Seven days later, she was spending the afternoon in town window shopping, having left her pain in her hospital room.
A miracle?
It looks like it.
But in medicine, even miracles need to be verified.
Hench therefore treats other patients, before inviting the cream of rheumatology to verify his statements.
Read also:
Cortisone: why it remains essential
“It was a one-of-a-kind experience. (…) A week of miraculous discovery, information exchange and collegiality, ”
said Richard Freyberg in the Mayo Clinic journal.
This article is for subscribers only.
You have 69% left to discover.
Subscribe: 1 € the first month
Can be canceled at any time
Enter your email
Already subscribed?
Log in
